Amyl therapeutics is a preclinical-stage biotechnology company that is focused on treating rare and severe peripheral protein misfolding diseases. It uses an amyloid fibrils-specific technology platform named ClariTY for the treatment of all forms of amyloidosis. Therapies based on the ClariTY technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins.